相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。The prognostic value of the preoperative lung immune prognostic index in patients with urothelial bladder cancer undergoing radical cystectomy
Koki Obayashi et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2022)
Clinical Significance of Serum Biomarkers in Stage IV Non-Small-Cell Lung Cancer Treated with PD-1 Inhibitors: LIPI Score, NLR, dNLR, LMR, and PAB
Jia Chen et al.
DISEASE MARKERS (2022)
Lower neutrophil-to-lymphocyte ratio and positive programmed cell death ligand-1 expression are favorable prognostic markers in patients treated with pembrolizumab for urothelial carcinoma
Yu Miyama et al.
CANCER MEDICINE (2022)
Focus on the Dynamics of Neutrophil-to-Lymphocyte Ratio in Cancer Patients Treated with Immune Checkpoint Inhibitors: A Meta-Analysis and Systematic Review
Yusheng Guo et al.
CANCERS (2022)
European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines
J. Alfred Witjes et al.
EUROPEAN UROLOGY (2021)
Predictive Impact of Prognostic Nutritional Index on Pembrolizumab for Metastatic Urothelial Carcinoma Resistant to Platinum-based Chemotherapy
Yudai Ishiyama et al.
ANTICANCER RESEARCH (2021)
Neutrophil-to-Lymphocyte Ratio as a Prognostic Biomarker for Patients With Metastatic Renal Cell Carcinoma Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
Xiuqiong Chen et al.
FRONTIERS IN ONCOLOGY (2021)
Prognostic value of lactate dehydrogenase for melanoma patients receiving anti-PD-1/PD-L1 therapy A meta-analysis
Jun Xu et al.
MEDICINE (2021)
Prognostic blood-based biomarkers in patients treated with neoadjuvant chemotherapy for urothelial carcinoma of the bladder: A systematic review
Ekaterina Laukhtina et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2021)
The Prediction Potential of the Pretreatment Lung Immune Prognostic Index for the Therapeutic Outcomes of Immune Checkpoint Inhibitors in Patients With Solid Cancer: A Systematic Review and Meta-Analysis
Hui Liu et al.
FRONTIERS IN ONCOLOGY (2021)
Prognostic value of derived neutrophil-to-lymphocyte ratio (dNLR) in patients with non-small cell lung cancer receiving immune checkpoint inhibitors: a meta-analysis
Tao Yang et al.
BMJ OPEN (2021)
Lactate dehydrogenase: a marker of diminished antitumor immunity
Sandra Van Wilpe et al.
ONCOIMMUNOLOGY (2020)
C-Reactive Protein and Cancer-Diagnostic and Therapeutic Insights
Peter C. Hart et al.
FRONTIERS IN IMMUNOLOGY (2020)
Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up
Y. Fradet et al.
ANNALS OF ONCOLOGY (2019)
Evaluation of the Lung Immune Prognostic Index for Prediction of Survival and Response in Patients Treated With Atezolizumab for NSCLC: Pooled Analysis of Clinical Trials
Michael J. Sorich et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Prognostic significance of serum lactate dehydrogenase in patients with breast cancer: a meta-analysis
Dongbo Liu et al.
CANCER MANAGEMENT AND RESEARCH (2019)
Predictive Impact of Peripheral Blood Markers and C-Reactive Protein in Nivolumab Therapy for Metastatic Renal Cell Carcinoma
Hiroki Ishihara et al.
TARGETED ONCOLOGY (2019)
Prognostic Value of the Lung Immune Prognostic Index for Patients Treated for Metastatic Non-Small Cell Lung Cancer
Dickran Kazandjian et al.
JAMA ONCOLOGY (2019)
The Lung Immune Prognostic Index Discriminates Survival Outcomes in Patients with Solid Tumors Treated with Immune Checkpoint Inhibitors
Daniel E. Meyers et al.
CANCERS (2019)
Peripheral Blood Biomarkers Associated with Clinical Outcome in Non-Small Cell Lung Cancer Patients Treated with Nivolumab
Junko Tanizaki et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Prognostic utility of baseline neutrophil-to-lymphocyte ratio in patients receiving immune checkpoint inhibitors: a review and meta-analysis
Danielle Benedict Sacdalan et al.
ONCOTARGETS AND THERAPY (2018)
Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer
Laura Mezquita et al.
JAMA ONCOLOGY (2018)
Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab
Mariaelena Capone et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Prognostic factors of daily blood examination for advanced melanoma patients treated with nivolumab
Hisako Okuhira et al.
BIOSCIENCE TRENDS (2018)
Prognostic Value of Lactate Dehydrogenase in Patients with Hepatocellular Carcinoma: A Meta-Analysis
Weihao Kong et al.
BIOMED RESEARCH INTERNATIONAL (2018)
Immunotherapy for Urothelial Carcinoma: Current Evidence and Future Directions
Abhishek Tripathi et al.
CURRENT UROLOGY REPORTS (2018)
The Prognostic Role of the Change in Neutrophil-to-Lymphocyte Ratio During Neoadjuvant Chemotherapy in Patients with Muscle-Invasive Bladder Cancer: A Retrospective, Multi-Institutional Study
Jeenan Kaiser et al.
BLADDER CANCER (2018)
Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab (vol 27, pg 732, 2016)
P. F. Ferrucci et al.
ANNALS OF ONCOLOGY (2018)
Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition
Markus V. Heppt et al.
EUROPEAN JOURNAL OF CANCER (2017)
Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab
Stefan Diem et al.
LUNG CANCER (2017)
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
J. Bellmunt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Low Pretreatment Neutrophil-to-Lymphocyte Ratio Predicts for Good Outcomes in Patients Receiving Neoadjuvant Chemotherapy Before Radical Cystectomy for Muscle Invasive Bladder Cancer
Oscar Buisan et al.
CLINICAL GENITOURINARY CANCER (2017)
Prognostic relevance of lactate dehydrogenase in advanced pancreatic ductal adenocarcinoma patients
Yuanyuan Xiao et al.
BMC CANCER (2017)
Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma
S. Diem et al.
BRITISH JOURNAL OF CANCER (2016)
Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab
Benjamin Weide et al.
CLINICAL CANCER RESEARCH (2016)
Prognostic role of lactate dehydrogenase in solid tumors: A systematic review and meta-analysis of 76 studies
Fausto Petrelli et al.
ACTA ONCOLOGICA (2015)
Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis
Arnoud J. Templeton et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2014)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)